Tag: Ulotaront

An estimated 24 million people worldwide live with schizophrenia, but only 31.3% receive specialist mental health care [1.7.1]. For them, the answer to 'What is the new schizophrenia pill?' is a recently approved drug called Cobenfy, representing a major therapeutic advance.

Affecting approximately 24 million people worldwide, schizophrenia is a serious mental disorder where treatment has long been dominated by similar-acting drugs [1.6.2]. So, what is the new medication for schizophrenia? The answer lies in a novel class of drugs, led by the recently FDA-approved Cobenfy (xanomeline-trospium) [1.2.3].

In 2019, ulotaront received Breakthrough Therapy Designation from the FDA for schizophrenia, based on promising Phase 2 trial results. This investigational drug, ulotaront, is a first-in-class trace amine-associated receptor 1 (TAAR1) agonist representing a new approach to treating psychiatric conditions with a distinct safety profile.